Literature DB >> 33509236

High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma.

Hao Shu1, Bin Yuan1, Yao Huang1, Lei Wang1, Bing He1, Qi Sun2, Luning Sun3.   

Abstract

OBJECTIVES: Previous studies showed overexpression of ABCG2 in a variety of tumor tissues, which could potentially indicate the probability of chemotherapy resistance. This study aimed to reveal the role of ABCG2 in the development of chemotherapy resistance and the prognosis of osteosarcoma (OS).
METHODS: Sixty-eight OS patients were included in this study. Tumor tissues were collected for each patient during surgery. DOX-resistant OS cell lines were induced by consecutive exposure of gradually increasing concentration of DOX to the parental cell lines. Lentivirus was used for the knockdown of ABCG2 in OS cells. Cells were treated with the gradient concentration of DOX, and the viability was assessed by CCK8 assay. Total RNA was isolated from the tumor tissues or tumor cells, and the expression of ABCG2 was analyzed by qPCR. The relationship between ABCG2 expression and clinicopathological characteristics of the patients was analyzed using Student's t test or the Chi-square test. The overall survival time was calculated by the Kaplan-Meier method and analyzed by the log-rank test. p < 0.05 was considered statistically significant.
RESULTS: DOX-resistant OS cells were successfully established through continuous exposure to DOX. Forty-eight hours after DOX exposure, the IC 50 value of DOX-resistant HOS cells and DOX-resistant U2OS was 3.5 μM and 3.25 μM, respectively. By contrast, those of the untreated HOS and U2OS cells were 1.15 μM and 0.93 μM, respectively (p < 0.01). The mRNA expression level of ABCG2 was significantly increased in DOX-resistant cell lines. The CCK-8 assay showed that the DOX-resistant HOS cells and DOX-resistant U2OS cells transfected with ShABCG2 were more sensitive to the DOX treatment than those transfected with ShCtrl. Analysis of gene expression in OS tissues showed remarkably higher expression of ABCG2 as compared with adjacent normal tissues (p < 0.01). Patients with high expression level of ABCG2 had obviously decreased overall survival time than the patients with normal expression (p < 0.01).
CONCLUSIONS: ABCG2 expression level was significantly associated with the resistance to chemotherapy and the overall survival of OS patients. ABCG2 may be a promising therapeutic target for OS patients.

Entities:  

Keywords:  ABCG2; Chemoresistance; Osteosarcoma; Prognosis

Mesh:

Substances:

Year:  2021        PMID: 33509236      PMCID: PMC7842061          DOI: 10.1186/s13018-021-02204-z

Source DB:  PubMed          Journal:  J Orthop Surg Res        ISSN: 1749-799X            Impact factor:   2.359


  24 in total

1.  Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.

Authors:  Shinji Mizuarai; Naohiko Aozasa; Hidehito Kotani
Journal:  Int J Cancer       Date:  2004-03-20       Impact factor: 7.396

2.  Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer.

Authors:  Sharad S Singhal; Jyotsana Singhal; Maya P Nair; A G Lacko; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Int J Oncol       Date:  2007-03       Impact factor: 5.650

3.  Limb Salvage Versus Amputation in Conventional Appendicular Osteosarcoma: a Systematic Review.

Authors:  Julio J Jauregui; Vidushan Nadarajah; Joseph Munn; Robert Pivec; Bhaveen H Kapadia; Daniel M Lerman; Aditya V Maheshwari
Journal:  Indian J Surg Oncol       Date:  2018-01-20

4.  Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison.

Authors:  Tracy A Marko; Brandon J Diessner; Logan G Spector
Journal:  Pediatr Blood Cancer       Date:  2016-02-29       Impact factor: 3.167

5.  CCN2 promotes drug resistance in osteosarcoma by enhancing ABCG2 expression.

Authors:  Hsiao-Chi Tsai; An-Chen Chang; Chun-Hao Tsai; Yuan-Li Huang; Lijun Gan; Chi-Kuan Chen; Shih-Chia Liu; Te-Yang Huang; Yi-Chin Fong; Chih-Hsin Tang
Journal:  J Cell Physiol       Date:  2018-10-14       Impact factor: 6.384

6.  Contrasting roles of the ABCG2 Q141K variant in prostate cancer.

Authors:  Kathryn M Sobek; Jessica L Cummings; Dean J Bacich; Denise S O'Keefe
Journal:  Exp Cell Res       Date:  2017-03-11       Impact factor: 3.905

7.  Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2.

Authors:  Hiroshi Nakagawa; Kanako Wakabayashi-Nakao; Ai Tamura; Yu Toyoda; Shoko Koshiba; Toshihisa Ishikawa
Journal:  FEBS J       Date:  2009-12       Impact factor: 5.542

8.  ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome.

Authors:  Daniela Damiani; Mario Tiribelli; Antonella Geromin; Angela Michelutti; Margherita Cavallin; Alessandra Sperotto; Renato Fanin
Journal:  Am J Hematol       Date:  2015-07-22       Impact factor: 10.047

Review 9.  Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.

Authors:  Kohji Noguchi; Kazuhiro Katayama; Junko Mitsuhashi; Yoshikazu Sugimoto
Journal:  Adv Drug Deliv Rev       Date:  2008-12-03       Impact factor: 15.470

10.  MiR-193a regulates chemoresistance of human osteosarcoma cells via repression of IRS2.

Authors:  Haiyan Wang; Fangfang Zhao; Shanbao Cai; Youguang Pu
Journal:  J Bone Oncol       Date:  2019-05-11       Impact factor: 4.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.